Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 6:12:20406207211027458.
doi: 10.1177/20406207211027458. eCollection 2021.

The use of tafasitamab in diffuse large B-cell lymphoma

Johannes Düll  1 , Max Topp  2 , Gilles Salles  3
Affiliations
Review

The use of tafasitamab in diffuse large B-cell lymphoma

Johannes Düll et al. Ther Adv Hematol. .

Abstract

Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized monoclonal anti-CD19 antibody that has recently been approved by the FDA in combination with lenalidomide for the treatment of relapsed/refractory (R/R) DLBCL in patients who are not eligible for ASCT. Tafasitamab has an Fc region which has been modified to have an increased affinity for Fcγ receptors, to potentiate antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis. Here, we review the development, mode of action and clinical data for tafasitamab in combination with lenalidomide in R/R DLBCL, and discuss the various ways in which this novel antibody could be utilized in the treatment sequence to improve clinical outcomes for patients with DLBCL.

Keywords: DLBCL; anti-CD19; clinical data; diffuse large B-cell lymphoma; lenalidomide; mode of action; monoclonal antibody; real-world evidence; tafasitamab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: GS reports non-financial support from MorphoSys, during the conduct of the study; other from MorphoSys, other from BMS, other from AbbVieˇ, other from Janssen, other from Merck, other from Novartis, other from Gilead/Kite, other from Epizyme, other from Celgene/BMS, other from Roche/Genentech, other from Takeda, other from Autolus, other from Genmab, other from Velosbio, outside the submitted work; in addition, GS has a patent WO2012010561A1 issued. MT has nothing to disclose. JD reports non-financial support from MorphoSys, during the conduct of the study.

Figures

Figure 1.
Figure 1.
Combination mechanism of action of tafasitamab and lenalidomide.
Figure 2.
Figure 2.
L-MIND schema.
Figure 3.
Figure 3.
Kaplan–Meier curves for (a) duration of response, (b) PFS and (c) OS.
Figure 4.
Figure 4.
Forest plots for (a) ORR, (b) 24-month duration of response and (c) 24-month OS.
Figure 5.
Figure 5.
AEs per patient-year during combination and monotherapy phases. *n = 40 includes 30 patients who completed 12 cycles of tafasitamab plus lenalidomide and continued tafasitamab monotherapy and 10 patients who discontinued lenalidomide but continued tafasitamab monotherapy. AE, adverse event; LEN, lenalidomide.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Solimando AG, Annese T, Tamma R, et al.. New insights into diffuse large B-cell lymphoma pathobiology. Cancers (Basel) 2020; 12: 1–22. - PMC - PubMed
    1. National Cancer Institute. SEER cancer stat facts: diffuse large B-cell lymphoma [Internet], https://seer.cancer.gov/statfacts/html/dlbcl.html (2019, accessed 4 January 2021).
    1. Coiffier B, Ementine Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure – what to do? Hematol Am Soc Hematol Educ Progr 2016; 2016: 366–378. - PMC - PubMed
    1. Crump M, Neelapu SS, Farooq U, et al.. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800–1808. - PMC - PubMed
    1. Zinzani PL, Pellegrini C, Gandolfi L, et al.. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462–466. - PubMed

LinkOut - more resources